Strategies of vendors in the global cancer cachexia therapeutics market.

The global cancer cachexia therapeutics market is expected to grow at a CAGR of 5.54% during the forecast period. Major vendors in the global cancer cachexia therapeutics market include AbbVie Inc., ANI Pharmaceuticals Inc., Bristol-Myers Squibb Co., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals Plc., Merck & Co. Inc., Mylan NV, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. among others.

Vendors are focusing on strategies such as M&As and partnerships to expand and strengthen their market base. For instance, AbbVie Inc., in June 2019, the company entered into a definitive transaction agreement to acquire Allergan Plc for approximately $63 billion. ANI Pharmaceuticals Inc., in August 2018, the company acquired WellSpring Pharma Services Inc. for $18 million in cash, to expand its contract manufacturing business.

Request for: Free Sample Report

Similarly, Bristol-Myers Squibb Co., in April 2019, the company announced at the special meeting of stockholders that its shareholders had voted to approve the issuance of shares of BMS common stock in connection with the company’s pending merger with Celgene Corp. Merck & Co. Inc., in June 2019, the company entered into a definitive agreement to acquire Tilos Therapeutics Inc. Hence, the increasing M&As and partnerships among vendors is expected to boost the growth of the global cancer cachexia therapeutics market during the forecast period.